Seeking Alpha
 

United Therapeutics Corporation (UTHR)

- NASDAQ
  • Wed, May 20, 5:41 PM
    | 3 Comments
  • Thu, Mar. 5, 8:52 AM
    • AbbVie's (NYSE:ABBV) extraordinarily generous buyout of Pharmacyclics (NASDAQ:PCYC) is a crystal clear example of how keen big pharma is to boost its prospects with biotech drugs with blockbuster potential. The transaction's $20B tab, backing out PCYC's $1B cash balance, values Imbruvica (ibrutinib) at $40B since Pharmacyclics' commercial partner Johnson & Johnson (NYSE:JNJ) gets 50% of Imbruvica's revenue. This implies a multiple of almost 7x Imbruvica's projected peak sales of $6B. By comparison, Amgen's (NASDAQ:AMGN) takeout of Onyx Pharma and Sanofi's (NYSE:SNY) takeout of Genzyme were both at 5x premiums.
    • The looming patent expiration for Humira ($12.5B in sales the past four quarters) undoubtedly provided AbbVie extra incentive to get the deal done.
    • Adding 50% of Imbruvica's sales to AbbVie's top line should increase its revenue growth 3 - 7% and EPS growth 8 - 11% through 2020.
    • According to RBC analyst Michael Yee, other biotechs on the big ticket acquisition radar are: BioMarin Pharmaceuticals (NASDAQ:BMRN), Dyax (NASDAQ:DYAX), Esperion Therapeutics (NASDAQ:ESPR), United Therapeutics (NASDAQ:UTHR), Vertex Pharmaceuticals (NASDAQ:VRTX), Intercept Pharmaceuticals (NASDAQ:ICPT), Juno Therapeutics (NASDAQ:JUNO), Kite Pharma (NASDAQ:KITE), PTC Therapeutics (NASDAQ:PTCT) and Receptos (NASDAQ:RCPT).
    | 5 Comments
  • Aug. 29, 2014, 12:45 PM
    | Comment!
  • Aug. 29, 2014, 11:52 AM
    • Shares of United Therapeutics (UTHR +23.1%) jump on 5x surge in volume after a court rules that Sandoz (NVS +0.3%) failed to prove that United's '007 and '117 Remodulin (treprostinil) patents are invalid and that United proved that Sandoz's ANDA will infringe on patent '117.
    • Remodulin accounted for almost 45% of United's 1H sales of $612.2M.
    | Comment!
  • Dec. 23, 2013, 5:35 PM
    • Supernus Pharmaceuticals (SUPN) shares spike 24%, adding to an 8% gain in regular trading, after the company announces the FDA has approved Orenitram extended-release tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.
    • The news broke last week, but it appears that investors have had in their memory that Supernus has a development/licensing agreement for the drug with United Therapeutics jolted by the PR.
    • Supernus developed the formulation under an agreement with United Therapeutics (UTHR +30.4%), whose shares rocketed when the approval was announced earlier today. United will pay Supernus certain milestone fees and royalties on global product sales.
    | 1 Comment
  • Dec. 23, 2013, 12:46 PM
    | Comment!
  • Dec. 23, 2013, 9:50 AM
    • Sarepta Therapeutics (SRPT +3.7%upgraded to Neutral from Underweight at Piper. Price target is $20.
    • United Therapeutics (UTHR +24.2%) upgraded to Outperform (from Market Perform) at BMO and to Neutral (from Underweight) at JPMorgan.
    • Surgical Care Affiliates (SCAI -1.1%) initiated at Outperform at BMO. Price target is $37.
    | Comment!
  • Dec. 23, 2013, 9:10 AM
    | Comment!
  • Apr. 25, 2013, 3:46 PM
    United Therapeutics (UTHR -3%) slides after its Q1 EPS results missed Street expectations earlier today. Revenue increased by nearly $41M over the prior year the period, with growth in product revenues reflecting the continuing increase in the number of patients being treated, but expenses in both R&D and SG&A pressured bottom line performance.
    | Comment!
  • Apr. 11, 2013, 11:15 AM
    United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.
    | 1 Comment
  • Mar. 25, 2013, 9:10 AM
    Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%
    | Comment!
  • Mar. 25, 2013, 6:11 AM
    The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR)
    | Comment!
  • Feb. 26, 2013, 1:26 PM
    After a valliant fight, United Therapeutics (UTHR -0.9%) gives up the days gains to trade in the red after Brean Murray cuts the shares to Hold on the back of its Q4 results posted earlier. The stock has had a good run since plummeting in October of last year on the FDA's rejection of Treprostinil, gaining nearly 30% and presently testing a 2-year high.
    | Comment!
  • Feb. 4, 2013, 11:17 AM
    United Therapeutics (UTHR +1.3%) moves up after its board authorizes an additional $420M to its existing share repurchase program. The program will become effective on March 4 and remain open for up to one year. Separately, Standpoint Research ups the shares from Hold to Buy.
    | Comment!
  • Oct. 24, 2012, 12:45 PM
    Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%.
    | Comment!
  • Oct. 24, 2012, 9:10 AM
    Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
    Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%.
    | Comment!
Visit Seeking Alpha's
UTHR vs. ETF Alternatives
Company Description
United Therapeutics Corp is a biotechnology company. The Company is engaged in thedevelopment and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.